Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $966 | $813 | $866 | $820 |
| Short-Term Investments | $1,728 | $1,627 | $1,326 | $1,616 |
| Receivables | $405 | $328 | $238 | $199 |
| Inventory | $79 | $89 | $129 | $86 |
| Other Curr. Assets | $117 | $126 | $133 | $0 |
| Total Curr. Assets | $3,295 | $2,983 | $2,692 | $2,809 |
| Property Plant & Equip (Net) | $694 | $726 | $739 | $734 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $117 | $10 | $0 | $0 |
| Other NC Assets | $134 | $111 | $115 | $101 |
| Total NC Assets | $945 | $847 | $854 | $835 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $4,240 | $3,830 | $3,546 | $3,643 |
| Liabilities | – | – | – | – |
| Payables | $88 | $56 | $98 | $73 |
| Short-Term Debt | $113 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $55 | $103 | $42 | $149 |
| Other Curr. Liab. | $214 | $177 | $171 | $131 |
| Total Curr. Liab. | $1,186 | $968 | $768 | $696 |
| LT Debt | $2,359 | $1,021 | $1,017 | $676 |
| Deferred Rev, NC | $0 | $188 | $194 | $152 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $398 | $1,631 | $1,465 | $1,250 |
| Total NC Liab. | $2,987 | $3,083 | $2,937 | $2,359 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $271 | $285 | $303 | $322 |
| Total Liabilities | $4,173 | $4,051 | $3,705 | $3,055 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1 | $1 | $1 | $1 |
| Retained Earnings | -$7,288 | -$7,010 | -$6,569 | -$5,438 |
| AOCI | -$35 | -$23 | -$45 | -$33 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $67 | -$221 | -$158 | $588 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $4,240 | $3,830 | $3,546 | $3,643 |
| Net Debt | $1,506 | $208 | $151 | -$144 |